Clinical trial
Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome
NCT02921893 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome
- Lead sponsor
- Mayo Clinic
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2016
- Completion date
- May 13, 2024
- Enrollment
- 21 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.